Cross-neutralization of Omicron subvariants after heterologous NVX-CoV2373 boosters: Comparison between prior SARS-CoV-2-infected and infection-naive individuals - 28/01/23

Min Joo Choi ^a, 1

  Choi MJ and Choi J contributed equally to this work.

, ^⁎, Ju-Yeon Choi ^b, 1

  Choi MJ and Choi J contributed equally to this work.

, Hakjun Hyun ^c, Eliel Nham ^c, Hye Seong ^c, Jin Gu Yoon ^c, Ji Yun Noh ^{c, d}, Hee Jin Cheong ^{c, d}, Woo Joo Kim ^{c, d}, Su-Hwan Kim ^b, Hyeonji Jeong ^b, Min-Seong Kim ^b, Byoungguk Kim ^{b, ⁎} , Joon Young Song ^{c, d, ⁎}

^a Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Republic of Korea 

^b Division of Vaccine Clinical Research, Center for Vaccine Research, National Institute of Infectious Diseases, Korea National Institute of Health, Cheongju, Republic of Korea 

^c Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea 

^d Vaccine Innovation Center-KU Medicine (VIC-K), Seoul, Republic of Korea 

^⁎Corresponding author.^⁎⁎Byoungguk KimKorea National Institute of Health, Cheongju, South KoreaByoungguk KimKorea National Institute of HealthCheongjuSouth Korea^⁎⁎⁎Joon Young Song MD, Ph.D., Korea University College of Medicine, Seoul, South KoreaJoon Young Song MD, Ph.D., Korea University College of MedicineSeoulSouth Korea